Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00898937|
Recruitment Status : Terminated (Funding ended)
First Posted : May 12, 2009
Results First Posted : April 13, 2018
Last Update Posted : April 13, 2018
RATIONALE: Studying samples of breast tissue in the laboratory may help doctors learn more about the genes and proteins found in breast tissue.
PURPOSE: This phase I trial is studying genes and proteins in breast tissue from women undergoing surgery for breast cancer or core biopsy of the breast.
|Condition or disease||Intervention/treatment|
|Breast Cancer||Genetic: microarray analysis Procedure: breast biopsy|
- Assess tumor gene expression information from women undergoing surgery for breast cancer or core biopsy sampling of the breast.
OUTLINE: This is a pilot study.
Tumor tissue is collected and analyzed for tumor gene expression by DNA microarray analysis for research studies.
PROJECTED ACCRUAL: A total of 100 patients will be accrued for this study.
|Study Type :||Observational|
|Actual Enrollment :||55 participants|
|Official Title:||Pilot Study for Analysis of Tumor Gene Expression by DNA Microarray Analysis in Patients Undergoing Breast Cancer Surgery or Core Biopsy Sampling|
|Study Start Date :||September 1999|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||July 2017|
- Genetic: microarray analysis
tumor specimen will be assessed by microarray analysis
- Procedure: breast biopsy
A breast biopsy will be done to obtain a tumor specimen
- Tumor Gene Expression as Assessed by RNA Microarray Analysis [ Time Frame: 1 day ]Concentration of RNA recovered from breast needle biopsies
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00898937
|United States, District of Columbia|
|Lombardi Comprehensive Cancer Center at Georgetown University Medical Center|
|Washington, District of Columbia, United States, 20007|
|Principal Investigator:||Claudine Isaacs, MD||Lombardi Comprehensive Cancer Center|